Clinical Trial Update: A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

A Phase 2 IMMA Master Protocol trial of LY3361237 in participants with at least moderately active systemic lupus erythematosus was terminated, with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• LY3361237

Snippet

Sponsor: Eli Lilly and Company | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: TERMINATED | Results posted: 2025-01-20